<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01993108</url>
  </required_header>
  <id_info>
    <org_study_id>HUM00047129</org_study_id>
    <nct_id>NCT01993108</nct_id>
  </id_info>
  <brief_title>Control of Cognition (Naltrexone, Methylphenidate, and ADHD Study (NMAS))</brief_title>
  <acronym>NMAS</acronym>
  <official_title>Control of Cognition: Naltrexone, Methylphenidate, and ADHD Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Michigan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Michigan</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this research is to understand the functioning of 'regulatory circuits' in the
      brain. We are also interested in how the medications methylphenidate and naltrexone affect
      these regulatory circuits. This research study will use a scanning technique known as
      functional magnetic resonance imaging (fMRI) which takes a special kind of picture of the
      brain that enables us to &quot;see the brain at work&quot;. Adult participants will be given a one-time
      dose of either methylphenidate, naltrexone,or placebo before each fMRI scan session.

      The main purpose for this research is to better understand the functioning of regulatory
      circuits in healthy individuals and individuals with psychiatric disorders. This research may
      one day help us develop better treatments for these disorders.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The goal of this research is to understand the functioning of 'regulatory circuits' in the
      brain. These are brain circuits which allow a person to regulate their attention, regulate
      their behavioral responses, and regulate their decision-making. We are also interested in how
      the medications methylphenidate and naltrexone affect these regulatory circuits.
      Methylphenidate is a widely-used, FDA approved medication used to treat Attention Deficit
      Hyperactivity Disorder (ADHD) and is also known as Ritalin. Naltrexone is an FDA approved
      medication used to help treat alcohol and substance abuse.

      This research study will use a scanning technique known as functional magnetic resonance
      imaging (fMRI)which takes a special kind of picture of the brain that enables us to &quot;see the
      brain at work&quot;. Adult participants will be given a one-time dose of either methylphenidate,
      naltrexone,or placebo before each fMRI scan session. There are three total fMRI scan
      sessions. Therefore, each participant will receive each possible medication/placebo only
      once.

      Using the fMRI technique, the main purpose of this research is to better understand the
      functioning of regulatory circuits in healthy individuals and individuals with psychiatric
      disorders. This research may one day help us develop better treatments for these disorders.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Actual">February 2017</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reaction Time Variability on the Multi-Source Interference Task</measure>
    <time_frame>2 hours</time_frame>
    <description>Multi-Source Interference Task is a psychological task that measures the psychological construct of cognitive control, the ability to suppress automatic response tendencies. Reaction time variability is the standard deviation of the trial to trial reaction time measured in seconds.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Reaction Time on the Multi-Source Interference Task</measure>
    <time_frame>Two hours</time_frame>
    <description>Reaction time of the Multi-Source Interference Task is measured in seconds.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Accuracy on the Multi-Source Interference Task</measure>
    <time_frame>Two hours</time_frame>
    <description>Accuracy is the calculated percentage of correct responses over total trials in the Multi-Source Interference Task.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Characterize the Effects of Methylphenidate and Naltrexone on Neural Circuits in Prefrontal Cortex Associated With Top-down Control.</measure>
    <time_frame>Two hours</time_frame>
    <description>The effects of methylphenidate, naltrexone, and placebo on the change in BOLD (Blood Oxygen Level Dependent) signal will be characterized in the incongruent condition (cognitive regulation condition) of the MSIT (multi-source interference task) relative to the congruent condition (no regulation condition). Specifically, the summed BOLD signal in three regions--dorsal lateral prefrontal cortex, anterior insula, anterior cingulate--are measured.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">23</enrollment>
  <condition>Healthy</condition>
  <condition>Attention Deficit Hyperactivity Disorder</condition>
  <arm_group>
    <arm_group_label>Healthy Controls</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy individuals will receive a one-time, randomized dose of 40mgs of Methylphenidate, 40mgs of Naltrexone, and a placebo one hour before the fMRI scanning session.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Adult Attention-Deficit/Hyperactivity Disorder</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ADHD individuals will receive a one-time, randomized dose of 40mgs of Methylphenidate, 40mgs of Naltrexone, and a placebo one hour before the fMRI scanning session.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methylphenidate</intervention_name>
    <description>One dose 40mgs of methylphenidate one hour before fMRI scanning.</description>
    <arm_group_label>Adult Attention-Deficit/Hyperactivity Disorder</arm_group_label>
    <arm_group_label>Healthy Controls</arm_group_label>
    <other_name>Ritalin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Naltrexone</intervention_name>
    <description>One dose 40mgs of naltrexone one hour before fMRI scanning.</description>
    <arm_group_label>Adult Attention-Deficit/Hyperactivity Disorder</arm_group_label>
    <arm_group_label>Healthy Controls</arm_group_label>
    <other_name>ReVia</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>One dose of placebo one hour before fMRI scanning.</description>
    <arm_group_label>Adult Attention-Deficit/Hyperactivity Disorder</arm_group_label>
    <arm_group_label>Healthy Controls</arm_group_label>
    <other_name>sugar pill</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria for all study participants:

          -  Right-Handedness

        Exclusion Criteria for all study participants:

          -  Any clinically significant history of cardiac problems

          -  Any current Axis I psychiatric diagnosis as verified by the Structured Clinical
             Interview for DSM-IV (other than participants with ADHD or history of alcohol
             dependence)

          -  A previous adequate trial with methylphenidate (Ritalin) or naltrexone (ReVia)

          -  Currently taking any psychoactive medications

          -  Any clinically significant medical condition

          -  Any clinically significant neurological problem (seizures, tics, serious head injury)

          -  Contraindications to MRI (metal objects in body or claustrophobia)

          -  Currently pregnant or lactating

          -  Alcohol or substance abuse (current or in the past 2 years)

          -  Left-handedness or ambidextrous

          -  Liver or kidney disease

        Inclusion Criteria for the participants with ADHD:

          -  Currently un-medicated adults with ADHD

          -  Has met full DSM-IV-R criteria (at least six of nine symptoms)for inattentive or
             hyperactive/impulsive subtypes (or both) by age 7 as well within the past month

          -  Has described a chronic course of ADHD symptomatology from childhood to adulthood

          -  Has endorsed a moderate or severe level of impairment attributed to the ADHD symptoms
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chandra Sekhar Sripada, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Michigan</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rachel Upjohn Building, East Medical Campus</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109-2700</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <study_first_submitted>November 13, 2013</study_first_submitted>
  <study_first_submitted_qc>November 20, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 25, 2013</study_first_posted>
  <results_first_submitted>March 20, 2018</results_first_submitted>
  <results_first_submitted_qc>May 17, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">June 18, 2018</results_first_posted>
  <last_update_submitted>May 17, 2018</last_update_submitted>
  <last_update_submitted_qc>May 17, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">June 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Michigan</investigator_affiliation>
    <investigator_full_name>Chandra Sekhar Sripada</investigator_full_name>
    <investigator_title>Assistant Professor of Psychiatry at the University of Michigan</investigator_title>
  </responsible_party>
  <keyword>Methylphenidate</keyword>
  <keyword>Naltrexone</keyword>
  <keyword>Placebo</keyword>
  <keyword>Neuroimaging</keyword>
  <keyword>Prefrontal Control Circuits</keyword>
  <keyword>Attention Control</keyword>
  <keyword>Motor Control</keyword>
  <keyword>Appetitive Control</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Attention Deficit Disorder with Hyperactivity</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Naltrexone</mesh_term>
    <mesh_term>Methylphenidate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Healthy Controls</title>
          <description>Healthy individuals will receive a one-time, randomized dose of 40mgs of Methylphenidate, 40mgs of Naltrexone, and a placebo one hour before the fMRI scanning session.
Methylphenidate: One dose 40mgs of methylphenidate one hour before fMRI scanning.
Naltrexone: One dose 40mgs of naltrexone one hour before fMRI scanning.
Placebo: One dose of placebo one hour before fMRI scanning.</description>
        </group>
        <group group_id="P2">
          <title>Adult Attention-Deficit/Hyperactivity Disorder</title>
          <description>ADHD individuals will receive a one-time, randomized dose of 40mgs of Methylphenidate, 40mgs of Naltrexone, and a placebo one hour before the fMRI scanning session.
Methylphenidate: One dose 40mgs of methylphenidate one hour before fMRI scanning.
Naltrexone: One dose 40mgs of naltrexone one hour before fMRI scanning.
Placebo: One dose of placebo one hour before fMRI scanning.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Healthy Controls</title>
          <description>Healthy individuals will receive a one-time, randomized dose of 40mgs of Methylphenidate, 40mgs of Naltrexone, and a placebo one hour before the fMRI scanning session.
Methylphenidate: One dose 40mgs of methylphenidate one hour before fMRI scanning.
Naltrexone: One dose 40mgs of naltrexone one hour before fMRI scanning.
Placebo: One dose of placebo one hour before fMRI scanning.</description>
        </group>
        <group group_id="B2">
          <title>Adult Attention-Deficit/Hyperactivity Disorder</title>
          <description>ADHD individuals will receive a one-time, randomized dose of 40mgs of Methylphenidate, 40mgs of Naltrexone, and a placebo one hour before the fMRI scanning session.
Methylphenidate: One dose 40mgs of methylphenidate one hour before fMRI scanning.
Naltrexone: One dose 40mgs of naltrexone one hour before fMRI scanning.
Placebo: One dose of placebo one hour before fMRI scanning.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="11"/>
            <count group_id="B2" value="12"/>
            <count group_id="B3" value="23"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24.9" spread="5.0"/>
                    <measurement group_id="B2" value="22.08" spread="3.4"/>
                    <measurement group_id="B3" value="23.4" spread="4.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Reaction Time Variability on the Multi-Source Interference Task</title>
        <description>Multi-Source Interference Task is a psychological task that measures the psychological construct of cognitive control, the ability to suppress automatic response tendencies. Reaction time variability is the standard deviation of the trial to trial reaction time measured in seconds.</description>
        <time_frame>2 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Methlyphenidate in Healthy Controls</title>
            <description>40mg methylphenidate in Healthy Controls</description>
          </group>
          <group group_id="O2">
            <title>Naltrexone in Healthy Controls</title>
            <description>40mg Naltrexone in Healthy Controls</description>
          </group>
          <group group_id="O3">
            <title>Placebo in Healthy Controls</title>
            <description>Placebo Pill in Healthy Controls</description>
          </group>
          <group group_id="O4">
            <title>Methlyphenidate in ADHD</title>
            <description>40mg methylphenidate in ADHD</description>
          </group>
          <group group_id="O5">
            <title>Naltrexone in ADHD</title>
            <description>40mg naltrexone in ADHD</description>
          </group>
          <group group_id="O6">
            <title>Placebo in ADHD</title>
            <description>Placebo Pill in ADHD</description>
          </group>
        </group_list>
        <measure>
          <title>Reaction Time Variability on the Multi-Source Interference Task</title>
          <description>Multi-Source Interference Task is a psychological task that measures the psychological construct of cognitive control, the ability to suppress automatic response tendencies. Reaction time variability is the standard deviation of the trial to trial reaction time measured in seconds.</description>
          <units>seconds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="11"/>
                <count group_id="O4" value="12"/>
                <count group_id="O5" value="12"/>
                <count group_id="O6" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".22" spread=".07"/>
                    <measurement group_id="O2" value=".23" spread=".06"/>
                    <measurement group_id="O3" value=".26" spread=".06"/>
                    <measurement group_id="O4" value=".20" spread=".06"/>
                    <measurement group_id="O5" value=".20" spread=".05"/>
                    <measurement group_id="O6" value=".21" spread=".06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>.02</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.03</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>.118</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>.02</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>.349</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Median Difference (Final Values)</param_type>
            <param_value>.02</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>.348</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Median Difference (Final Values)</param_type>
            <param_value>.02</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Reaction Time on the Multi-Source Interference Task</title>
        <description>Reaction time of the Multi-Source Interference Task is measured in seconds.</description>
        <time_frame>Two hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Methlyphenidate in Healthy Controls</title>
            <description>40mg methylphenidate in healthy controls</description>
          </group>
          <group group_id="O2">
            <title>Naltrexone in Healthy Controls</title>
            <description>40mg Naltrexone in healthy controls</description>
          </group>
          <group group_id="O3">
            <title>Placebo in Healthy Controls</title>
            <description>Placebo pill in healthy controls</description>
          </group>
          <group group_id="O4">
            <title>Methlyphenidate in ADHD</title>
            <description>40mg methylphenidate in ADHD</description>
          </group>
          <group group_id="O5">
            <title>Naltrexone in ADHD</title>
            <description>40mg naltrexone in ADHD</description>
          </group>
          <group group_id="O6">
            <title>Placebo in ADHD</title>
            <description>placebo pill in ADHD</description>
          </group>
        </group_list>
        <measure>
          <title>Reaction Time on the Multi-Source Interference Task</title>
          <description>Reaction time of the Multi-Source Interference Task is measured in seconds.</description>
          <units>seconds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="11"/>
                <count group_id="O4" value="12"/>
                <count group_id="O5" value="12"/>
                <count group_id="O6" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".78" spread=".12"/>
                    <measurement group_id="O2" value=".83" spread=".10"/>
                    <measurement group_id="O3" value=".85" spread=".14"/>
                    <measurement group_id="O4" value=".71" spread=".10"/>
                    <measurement group_id="O5" value=".73" spread=".09"/>
                    <measurement group_id="O6" value=".77" spread=".10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>.019</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>.07</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>.240</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>.02</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>.081</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Median Difference (Final Values)</param_type>
            <param_value>.06</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>.247</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Median Difference (Final Values)</param_type>
            <param_value>.04</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Accuracy on the Multi-Source Interference Task</title>
        <description>Accuracy is the calculated percentage of correct responses over total trials in the Multi-Source Interference Task.</description>
        <time_frame>Two hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Methlyphenidate in Healthy Controls</title>
            <description>40mg methylphenidate in Healthy Controls</description>
          </group>
          <group group_id="O2">
            <title>Naltrexone in Healthy Controls</title>
            <description>40mg Naltrexone in Healthy Controls</description>
          </group>
          <group group_id="O3">
            <title>Placebo in Healthy Controls</title>
            <description>Placebo pill in Healthy Controls</description>
          </group>
          <group group_id="O4">
            <title>Methlyphenidate in ADHD</title>
            <description>40mg methlyphenidate in ADHD</description>
          </group>
          <group group_id="O5">
            <title>Naltrexone in ADHD</title>
            <description>40mg naltrexone in ADHD</description>
          </group>
          <group group_id="O6">
            <title>Placebo in ADHD</title>
            <description>Placebo pill in ADHD</description>
          </group>
        </group_list>
        <measure>
          <title>Accuracy on the Multi-Source Interference Task</title>
          <description>Accuracy is the calculated percentage of correct responses over total trials in the Multi-Source Interference Task.</description>
          <units>percent of total trials</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="11"/>
                <count group_id="O4" value="12"/>
                <count group_id="O5" value="12"/>
                <count group_id="O6" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96" spread="2"/>
                    <measurement group_id="O2" value="93" spread="7"/>
                    <measurement group_id="O3" value="91" spread="8"/>
                    <measurement group_id="O4" value="93" spread="10"/>
                    <measurement group_id="O5" value="93" spread="8"/>
                    <measurement group_id="O6" value="92" spread="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>.049</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>.05</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>.497</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>.02</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>.814</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>.593</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>.01</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Characterize the Effects of Methylphenidate and Naltrexone on Neural Circuits in Prefrontal Cortex Associated With Top-down Control.</title>
        <description>The effects of methylphenidate, naltrexone, and placebo on the change in BOLD (Blood Oxygen Level Dependent) signal will be characterized in the incongruent condition (cognitive regulation condition) of the MSIT (multi-source interference task) relative to the congruent condition (no regulation condition). Specifically, the summed BOLD signal in three regions--dorsal lateral prefrontal cortex, anterior insula, anterior cingulate--are measured.</description>
        <time_frame>Two hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Methlyphenidate in Healthy Controls</title>
            <description>40mg methylphenidate in Healthy Controls</description>
          </group>
          <group group_id="O2">
            <title>Naltrexone in Healthy Controls</title>
            <description>40mg Naltrexone in Healthy Controls</description>
          </group>
          <group group_id="O3">
            <title>Placebo in Healthy Controls</title>
            <description>Placebo pill in Healthy Controls</description>
          </group>
          <group group_id="O4">
            <title>Methlyphenidate in ADHD</title>
            <description>40mg methlyphenidate in ADHD</description>
          </group>
          <group group_id="O5">
            <title>Naltrexone in ADHD</title>
            <description>40mg naltrexone in ADHD</description>
          </group>
          <group group_id="O6">
            <title>Placebo in ADHD</title>
            <description>Placebo pill in ADHD</description>
          </group>
        </group_list>
        <measure>
          <title>Characterize the Effects of Methylphenidate and Naltrexone on Neural Circuits in Prefrontal Cortex Associated With Top-down Control.</title>
          <description>The effects of methylphenidate, naltrexone, and placebo on the change in BOLD (Blood Oxygen Level Dependent) signal will be characterized in the incongruent condition (cognitive regulation condition) of the MSIT (multi-source interference task) relative to the congruent condition (no regulation condition). Specifically, the summed BOLD signal in three regions--dorsal lateral prefrontal cortex, anterior insula, anterior cingulate--are measured.</description>
          <units>Mean percentage of BOLD signal change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="11"/>
                <count group_id="O4" value="12"/>
                <count group_id="O5" value="12"/>
                <count group_id="O6" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".21" spread=".51"/>
                    <measurement group_id="O2" value=".51" spread=".58"/>
                    <measurement group_id="O3" value=".20" spread=".45"/>
                    <measurement group_id="O4" value=".43" spread=".40"/>
                    <measurement group_id="O5" value=".58" spread=".59"/>
                    <measurement group_id="O6" value=".47" spread=".56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>.926</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>.01</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>.126</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>.31</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>.852</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>.04</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>.552</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Median Difference (Final Values)</param_type>
            <param_value>.11</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Subjects were observed for 2.5 to 3 hours during the course of each of the three scanning sessions.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Methlyphenidate</title>
          <description>40mg methylphenidate</description>
        </group>
        <group group_id="E2">
          <title>Naltrexone</title>
          <description>40mg Naltrexone</description>
        </group>
        <group group_id="E3">
          <title>Placebo</title>
          <description>Placebo</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Chandra Sripada</name_or_title>
      <organization>University of Michigan</organization>
      <phone>734 232 0281</phone>
      <email>sripada@umich.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

